PANTOPRAZOLE
Huntington's Disease
Massachusetts General HospitalSmall moleculePhase 3Dormant
B
59/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 44/ 100
- Competitive Position
- 89/ 100
Competitive context
3 Active assets in the Huntington's Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tetrabenazine William Ondo, MD | Phase 4 | BBB |
Dimebon Medivation, Inc. | Phase 3 | BB |
sen0014196 Siena Biotech S.p.A. | Phase 2 | BB |
coq10 Johns Hopkins University | Phase 3 | B |
Calcium folinate pentahydrate Massachusetts General Hospital | Phase 3 | B |
View all 32 →
Same molecule, other indications
PANTOPRAZOLE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →